Impact of body fat distribution and sarcopenia on the overall survival in patients with spinal metastases receiving radiotherapy treatment: a prospective cohort study

References

• Macedo F, Ladeira K, Pinho F, et al. Bone metastases: an overview. Oncol Rev. 2017;11(1):321–321.
   PubMed Web of Science ®Google Scholar
• Martin L, Birdsell L, Macdonald N, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. JCO. 2013;31(12):1539–1547.
   PubMed Web of Science ®Google Scholar
• Huisman M, van der Velden JM, van Vulpen M, et al. Spinal instability as defined by the spinal instability neoplastic score is associated with radiotherapy failure in metastatic spinal disease. Spine J. 2014;14(12):2835–2840.
   PubMed Web of Science ®Google Scholar
• Kaloostian PE, Yurter A, Zadnik PL, et al. Current paradigms for metastatic spinal disease: an evidence-based review. Ann Surg Oncol. 2014;21(1):248–262.
   PubMed Web of Science ®Google Scholar
• Laufer I, Sciubba DM, Madera M, et al. Surgical management of metastatic spinal tumors. Cancer Control. 2012;19(2):122–128.
   PubMed Web of Science ®Google Scholar
• Verlaan JJ, Choi D, Versteeg A, et al. Characteristics of patients who survived < 3 months or > 2 years after surgery for spinal metastases: can we avoid inappropriate patient selection? J Clin Oncol. 2016;34(25):3054–3061.
   PubMed Web of Science ®Google Scholar
• Bickels J, Dadia S, Lidar Z. Surgical management of metastatic bone disease. J Bone Joint Surg Am. 2009;91(6):1503–1516.
   PubMedGoogle Scholar
• Bollen L, Wibmer C, Van der Linden YM, et al. Predictive value of six prognostic scoring systems for spinal bone metastases: an analysis based on 1379 patients. Spine. 2016;41(3):E155–162.
   PubMed Web of Science ®Google Scholar
• Okamura A, Watanabe M, Mine S, et al. Clinical impact of abdominal fat distribution on prognosis after esophagectomy for esophageal squamous cell carcinoma. Ann Surg Oncol. 2016;23(4):1387–1394.
   PubMed Web of Science ®Google Scholar
• Ebadi M, Martin L, Ghosh S, et al. Subcutaneous adiposity is an independent predictor of mortality in cancer patients. Br J Cancer. 2017;117(1):148–155.
   PubMed Web of Science ®Google Scholar
• Grignol VP, Smith AD, Shlapak D, et al. Increased visceral to subcutaneous fat ratio is associated with decreased overall survival in patients with metastatic melanoma receiving anti-angiogenic therapy. Surg Oncol. 2015;24(4):353–358.
   PubMed Web of Science ®Google Scholar
• Yip C, Dinkel C, Mahajan A, et al. Imaging body composition in cancer patients: visceral obesity, sarcopenia and sarcopenic obesity may impact on clinical outcome. Insights Imaging. 2015;6(4):489–497.
   PubMed Web of Science ®Google Scholar
• Antoun S, Lanoy E, Iacovelli R, et al. Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies. Cancer. 2013;119(18):3377–3384.
   PubMed Web of Science ®Google Scholar
• Prado CM, Lieffers JR, McCargar LJ, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008;9(7):629–635.
   PubMed Web of Science ®Google Scholar
• van Vugt JLA, Gaspersz MP, Vugts J, et al. Low skeletal muscle density is associated with early death in patients with perihilar cholangiocarcinoma regardless of subsequent treatment. Dig Surg. 2018;36(2):144–152.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.
   PubMedGoogle Scholar
• Irlbeck T, Massaro JM, Bamberg F, et al. Association between single-slice measurements of visceral and abdominal subcutaneous adipose tissue with volumetric measurements: the Framingham Heart Study. Int J Obes. 2010;34(4):781–787.
   Web of Science ®Google Scholar
• Bol GH, Kotte ANTJ, van der Heide UA, et al. Simultaneous multi-modality ROI delineation in clinical practice. Comput Methods Programs Biomed. 2009;96(2):133–140.
   PubMed Web of Science ®Google Scholar
• Mourtzakis M, Prado CMM, Lieffers JR, et al. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab. 2008;33(5):997–1006.
   PubMed Web of Science ®Google Scholar
• IBM Corp. Released 2013. IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY: IBM Corp.
   Google Scholar
• Shachar SS, Williams GR, Muss HB, et al. Prognostic value of sarcopenia in adults with solid tumours: A meta-analysis and systematic review. Eur J Cancer. 2016;57:58–67.
   PubMed Web of Science ®Google Scholar
• O'Brien R. A caution regarding rules of thumb for variance inflation factors. Qual Quant. 2007;41:673–690.
   Web of Science ®Google Scholar
• Schoenfeld D. Partial residuals for the proportional hazards regression model. Biometrika. 1982;69(1):239–241.
   Web of Science ®Google Scholar
• Roberts TT, Leonard GR, Cepela DJ. Classifications in brief: American Spinal Injury Association (ASIA) Impairment Scale. Clin Orthop Relat Res. 2017;475(5):1499–1504.
   PubMed Web of Science ®Google Scholar
• Mizuno R, Miyajima A, Hibi T, et al. Impact of baseline visceral fat accumulation on prognosis in patients with metastatic renal cell carcinoma treated with systemic therapy. Med Oncol. 2017;34(4):47.
   PubMed Web of Science ®Google Scholar
• Camus V, Lanic H, Kraut J, et al. Prognostic impact of fat tissue loss and cachexia assessed by computed tomography scan in elderly patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Eur J Haematol. 2014;93(1):9–18.
   PubMed Web of Science ®Google Scholar
• Tan BH, Birdsell LA, Martin L, et al. Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res. 2009;15(22):6973–6979.
   PubMed Web of Science ®Google Scholar
• Rutten IJ, Ubachs J, Kruitwagen RF, et al. The influence of sarcopenia on survival and surgical complications in ovarian cancer patients undergoing primary debulking surgery. Eur J Surg Oncol. 2017;43(4):717–724.
   PubMed Web of Science ®Google Scholar
• Chambard L, Girard N, Ollier E, et al. Bone, muscle, and metabolic parameters predict survival in patients with synchronous bone metastases from lung cancers. Bone. 2018;108:202–209.
   PubMed Web of Science ®Google Scholar
• Kim KM, Jang HC, Lim S. Differences among skeletal muscle mass indices derived from height-, weight-, and body mass index-adjusted models in assessing sarcopenia. Korean J Intern Med. 2016;31(4):643–650.
   PubMed Web of Science ®Google Scholar
• Ha Y, Kim D, Han S, et al. Sarcopenia predicts prognosis in patients with newly diagnosed hepatocellular carcinoma, independent of tumor stage and liver function. Cancer Res Treat. 2018;50(3):843–851.
   PubMedGoogle Scholar
• Rier HN, Jager A, Sleijfer S, et al. Low muscle attenuation is a prognostic factor for survival in metastatic breast cancer patients treated with first line palliative chemotherapy. The Breast. 2017;31:9–15.
   PubMed Web of Science ®Google Scholar
• Black D, Mackay C, Ramsay G, et al. Prognostic value of computed tomography: measured parameters of body composition in primary operable gastrointestinal cancers. Ann Surg Oncol. 2017;24(8):2241–2251.
   PubMed Web of Science ®Google Scholar
• Friedman J, Lussiez A, Sullivan J, et al. Implications of sarcopenia in major surgery. Nutr Clin Pract. 2015;30(2):175–179.
   PubMed Web of Science ®Google Scholar
• Pamoukdjian F, Bouillet T, Levy V, et al. Prevalence and predictive value of pre-therapeutic sarcopenia in cancer patients: a systematic review. Clin Nutr. 2018;37(4):1101–1113.
   PubMed Web of Science ®Google Scholar
• Tournadre A, Vial G, Capel F, et al. Sarcopenia. Joint Bone Spine. 2019;86(3):309–314.
   PubMed Web of Science ®Google Scholar
• Katagiri H, Okada R, Takagi T, et al. New prognostic factors and scoring system for patients with skeletal metastasis. Cancer Med. 2014;3(5):1359–1367.
   PubMed Web of Science ®Google Scholar
• Karhade AV, Shin JH, Schwab JH. Prognostic models for spinal metastatic disease: evolution of methodologies, limitations, and future opportunities. Ann Transl Med. 2019;7(10):219.
   PubMed Web of Science ®Google Scholar